Salveen Richter
Goldman Sachs Group, Inc., Research Division

Good morning, everyone. Thank you so much for joining us. It's my pleasure to introduce the Apogee team. With us, we have Jane Pritchett Henderson, Chief Financial Officer; and Jeff Hartness, Chief Commercial Officer. Thank you for joining us.

Salveen Richter
Goldman Sachs Group, Inc., Research Division

Maybe to start here, on the back of a few key data sets that have read out this year, including the 52-week zumi data in atopic dermatitis and recent dose escalation data in the disease as well, can you outline how the company is positioned in the second half and beyond and walk through the key near-term catalysts?

Jane Pritchett Henderson
Chief Financial Officer

Yes, absolutely, and thank you for having us, Salveen. Apogee is developing zumilokibart, our IL-13 targeting antibody across type 2 inflammatory diseases. Our first priority is moderate to severe atopic dermatitis. It is the largest of the I&I indications. It is growing the fastest. It is the least penetrated. So far, '26 has been a big year for us in terms of data. Our Phase II Part B data that we disclosed last month showed robust efficacy across lesional and itch endpoints with only 4 dosing days compared to 9 with standard of care.

Earlier this year, we reported Part A maintenance data, where not only we showed maintenance response, but importantly, we showed response that continue to improve to 52 weeks, including something very notable, EASI-100, which is very clear skin of over 40% for patients in that maintenance setting. What